BIOTECH- Vorsicht - 500 Beiträge pro Seite

[tradingboss]

Liebes Board,

lieber untergewichten aus charttechnischer Sicht :

- GPC : KZ:3,50€
- Evotec : KZ:3,00€

mit freundlichen Gruessen

[rene11]

noch einer der großmütig an andere denkt vielen dank, .. und vielleicht kommst ja auch noch billig rein, so als uneigennütziger nebeneffekt

[tradingboss]

@rene : ich habe mit gpc schon längst kasse gemacht und werde auch irgenwann wieder einsteigen aber auf jeden Fall unter 4,00€ definitiv!!

[linklink]

Das haste heute aber wohl verpasst...

[rene11]

na ja, jeder hat so seine eigene taktik, ... mal sehen, ob meine aufgeht, ha, ha

[siebtesinn]

ein Tip !!! ochid biosciences

Orchid BioSciences, Inc. Reports Strong First Quarter 2003 Financial ...

PRINCETON, N.J., May 8 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. , the leader in profiling genetic uniqueness, today reported financial results for the three months ended March 31, 2003.

For the first quarter of 2003, total revenues were \$12.7 million, up from \$11.7 million for the same period in 2002, an increase of 9%. Service revenues for the first quarter of 2003 were \$12.5 million, up from \$10.2 million from the same period in 2002, an increase of \$2.4 million or 23%. This increase is primarily from growth in Orchid``s forensic, paternity and public health genoprofiling service businesses. The results of continuing operations for both 2003 and 2002 exclude the revenues and operating expenses of the Company``s discontinued Orchid Diagnostics business unit, which it is currently seeking to divest. Revenues attributed to Orchid Diagnostics were \$2.7 million and \$4.1 million during the first quarter of 2003 and 2002, respectively. Product and other revenues were \$0.2 million for the first quarter of 2003, down from \$1.5 million for the comparable period in 2002. The decline in product and other revenues was due to the sale of the Orchid Life Sciences product business in the fourth quarter of 2002 and a decline in licensing revenue compared to 2002.

Orchid reported a loss from continuing operations of \$4.1 million, or \$0.09 per share allocable to common stockholders for the first quarter of 2003, compared to \$11.0 million, or \$0.22 per share, for the comparable period in 2002. The Company reported a loss from the Orchid Diagnostics discontinued operations of \$0.2 million, or \$0.00 per share, for the first quarter of 2003. Orchid reported a net loss allocable to common stockholders of \$5.0 million, or \$0.09 per share, f

[rene11]

wieder über 4,2, ... das sieht etwas besser aus

[linklink]

Tendenz weiter steigend. Es wird schön aus dem Ask gekauft, Bid zieht nach...